Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | IDE | P14735 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045277 | 0.83 | ALDH1A1 (0.36) | SMN1; SMN2LMNAALDH1A1POLBTSHR | |
| SCHEMBL26688580 | 0.81 | PSIP1 (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8134166 | 0.80 | TXNRD1 (0.32) | POLBTSHRMAPK1 | |
| SCHEMBL3305889 | 0.80 | MAPT (0.49) | SMN1; SMN2LMNAALDH1A1POLBTSHR | |
| SCHEMBL28826106 | 0.79 | PTGS2 (0.37) | SMN1; SMN2PTGS2PTGS1LMNA | |
| SCHEMBL7476629 | 0.79 | ALDH1A1 (0.42) | SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL1448262 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2PTGS2LMNAALDH1A1G6PD | |
| SCHEMBL8129522 | 0.76 | MMP13 (0.38) | — | |
| SCHEMBL28247559 | 0.76 | ALDH1A1 (0.54) | SMN1; SMN2LMNAALDH1A1POLBTSHR | |
| SCHEMBL7311145 | 0.74 | HPGD (0.40) | SMN1; SMN2LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | claimed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | claimed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | claimed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | claimed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | claimed |
| CN-117986235-A | P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023225477-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-115003299-A | Methods and compounds for restoring function of mutant p53 | 皮姆维制药公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-4670445-A | VASODILATORS | ELI LILLY AND COMPANY (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0113236-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES-PYRAZINES, AND -TRIAZINES | ELI LILLY AND COMPANY (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4636502-A | Methods of producing a positive inotropic effect or vasodilation by administration of 2-phenyl imidazo pyrimidines and pyrazines | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4578387-A | VASODILATION; DERIVATIVES OF 2-PHENYL-5,6,7,8-TETRAHYDROIMADAZO/1,2-A/PYRAZINE | ELI LILLY AND COMPANY (US) | 1986-03-25 | — | — | US | disclosed |
| US-4537889-A | PHENYL SUBSTITUTED IMIDAZO COMPOUNDS | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0113236-A1 | Substituted imidazopyrimidines-pyrazines, and -triazines | ELI LILLY AND COMPANY (US) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1363/4885PTGS2 3746/4885PTGS1 2755/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1363/4885PTGS2 3746/4885PTGS1 2755/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1363/4885PTGS2 3746/4885PTGS1 2755/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1363/4885PTGS2 3746/4885PTGS1 2755/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1363/4885PTGS2 3746/4885PTGS1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.